HU14.18K322A is under clinical development by Renaissance Pharma and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs for Neuroblastoma have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HU14.18K322A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HU14.18K322A overview

HU14.18K322A is under investigation for the treatment of neuroblastoma. The drug candidate is administered through intravenous route. HU14.18K322A is a humanized monoclonal anti-GD2 antibody. GD2, an O-acetylated disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves. It was also under development for the treatment of refractory or relapsed osteosarcoma, neuroblastoma, Ewing sarcoma and melanoma.

Renaissance Pharma overview

Renaissance Pharma, a subsidiary of Essential Holdings Ltd, operates in the pharmaceuticals and healthcare industry, specializing in oncology therapy area. It focuses on developing medications for the prevention and treatment of neuroblastoma in children. The company is headquartered in Altrincham, Cheshire, the UK.

For a complete picture of HU14.18K322A’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.